NeuroSense Therapeutics Ltd. NRSN
6.95
(0.45)
(6.08%)
as of 25 Sep
- Market cap
- $14.0M
- P/E
- 0.0×
Follow NRSN
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Mar '24 | Jun '24 | Sep '24 | Jun '25 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
0.26 | 0.46 | 0.21 | 0.71 |
Net Debt/EBITDA |
0.24 | 0.00 | 0.00 | 0.00 | |
Debt/Assets |
3.80% | 1.96% | 1.93% | 0.00% | |
Debt/Equity |
(0.01) | (0.02) | (0.01) | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.00 | 0.00 | — | 0.00 | |
Capex/Depreciation |
— | (0.27) | — | (0.62) | |
Interest Coverage |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
0.00 | 0.00 | — | 0.00 | |
Cash per Share |
1.00 | 0.00 | 0.00 | 0.00 | |
Shareholders Equity per Share |
(9.08) | 0.00 | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | — | |
Book value per Share |
(9.08) | 0.00 | 0.00 | 0.00 | |
Free Cash Flow |
— | (5.75) | — | (4.00) | |
Working Capital |
(3.34) | (1.89) | (3.00) | (0.65) | |
Capital Expenditures |
— | 0.00 | — | 0.00 | |
Net Current Asset Value |
(7.25) | (1.92) | (3.02) | (0.65) | |
| Other line items | |||||
Quick Ratio |
0.26 | 0.46 | 0.21 | 0.71 | |
Revenue per Share |
0.00 | — | — | — | |
Operating CF per Share |
0.00 | 0.00 | — | 0.00 | |
Capex per Share |
0.00 | 0.00 | — | 0.00 | |
Average Receivables |
0.49 | 0.41 | 0.36 | 0.54 | |
Average Payables |
1.40 | 1.29 | 1.15 | 1.28 | |
Average Assets |
3.39 | 4.85 | 3.19 | 2.43 | |
Average Common Equity |
(2.05) | (1.62) | (1.51) | (1.14) | |
Capex to Sales |
— | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | — | — | — |
Columns are period end dates